nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—PGR—corpus luteum—testicular cancer	0.064	0.127	CbGeAlD
Levonorgestrel—SHBG—seminiferous tubule of testis—testicular cancer	0.0602	0.119	CbGeAlD
Levonorgestrel—CYP19A1—corpus luteum—testicular cancer	0.0576	0.114	CbGeAlD
Levonorgestrel—AR—scrotum—testicular cancer	0.0556	0.11	CbGeAlD
Levonorgestrel—CYP19A1—seminiferous tubule of testis—testicular cancer	0.0488	0.0966	CbGeAlD
Levonorgestrel—AR—seminiferous tubule of testis—testicular cancer	0.0432	0.0856	CbGeAlD
Levonorgestrel—SHBG—semen—testicular cancer	0.0333	0.0659	CbGeAlD
Levonorgestrel—CYP19A1—semen—testicular cancer	0.027	0.0534	CbGeAlD
Levonorgestrel—AR—semen—testicular cancer	0.0239	0.0473	CbGeAlD
Levonorgestrel—SRD5A1—gonad—testicular cancer	0.014	0.0277	CbGeAlD
Levonorgestrel—SRD5A1—testis—testicular cancer	0.0101	0.02	CbGeAlD
Levonorgestrel—PGR—Ovarian Infertility Genes—DAZL—testicular cancer	0.00974	0.39	CbGpPWpGaD
Levonorgestrel—CYP19A1—Ovarian Infertility Genes—DAZL—testicular cancer	0.00639	0.256	CbGpPWpGaD
Levonorgestrel—ESR1—embryo—testicular cancer	0.0053	0.0105	CbGeAlD
Levonorgestrel—SHBG—gonad—testicular cancer	0.0051	0.0101	CbGeAlD
Levonorgestrel—AR—seminal vesicle—testicular cancer	0.00507	0.01	CbGeAlD
Levonorgestrel—SHBG—female gonad—testicular cancer	0.00415	0.00821	CbGeAlD
Levonorgestrel—CYP19A1—gonad—testicular cancer	0.00414	0.00819	CbGeAlD
Levonorgestrel—PGR—female gonad—testicular cancer	0.00374	0.00739	CbGeAlD
Levonorgestrel—SHBG—testis—testicular cancer	0.00368	0.00728	CbGeAlD
Levonorgestrel—AR—gonad—testicular cancer	0.00366	0.00725	CbGeAlD
Levonorgestrel—ESR1—gonad—testicular cancer	0.00359	0.00711	CbGeAlD
Levonorgestrel—CYP19A1—female gonad—testicular cancer	0.00336	0.00665	CbGeAlD
Levonorgestrel—PGR—testis—testicular cancer	0.00331	0.00656	CbGeAlD
Levonorgestrel—CYP19A1—testis—testicular cancer	0.00298	0.0059	CbGeAlD
Levonorgestrel—AR—female gonad—testicular cancer	0.00298	0.00589	CbGeAlD
Levonorgestrel—ESR1—female gonad—testicular cancer	0.00292	0.00578	CbGeAlD
Levonorgestrel—AR—testis—testicular cancer	0.00264	0.00522	CbGeAlD
Levonorgestrel—ESR1—testis—testicular cancer	0.00259	0.00513	CbGeAlD
Levonorgestrel—PGR—lymph node—testicular cancer	0.0024	0.00475	CbGeAlD
Levonorgestrel—CYP19A1—lymph node—testicular cancer	0.00216	0.00428	CbGeAlD
Levonorgestrel—AR—lymph node—testicular cancer	0.00191	0.00379	CbGeAlD
Levonorgestrel—ESR1—lymph node—testicular cancer	0.00188	0.00372	CbGeAlD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000815	0.0327	CbGpPWpGaD
Levonorgestrel—ESR1—LKB1 signaling events—STK11—testicular cancer	0.000625	0.025	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000561	0.0225	CbGpPWpGaD
Levonorgestrel—Dysuria—Epirubicin—testicular cancer	0.000534	0.00114	CcSEcCtD
Levonorgestrel—Abdominal distension—Doxorubicin—testicular cancer	0.000532	0.00113	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000531	0.00113	CcSEcCtD
Levonorgestrel—Asthma—Doxorubicin—testicular cancer	0.000528	0.00112	CcSEcCtD
Levonorgestrel—Influenza—Doxorubicin—testicular cancer	0.000528	0.00112	CcSEcCtD
Levonorgestrel—Pollakiuria—Epirubicin—testicular cancer	0.000527	0.00112	CcSEcCtD
Levonorgestrel—Asthenia—Ifosfamide—testicular cancer	0.000526	0.00112	CcSEcCtD
Levonorgestrel—Weight increased—Epirubicin—testicular cancer	0.00052	0.00111	CcSEcCtD
Levonorgestrel—Pruritus—Ifosfamide—testicular cancer	0.000519	0.0011	CcSEcCtD
Levonorgestrel—Weight decreased—Epirubicin—testicular cancer	0.000517	0.0011	CcSEcCtD
Levonorgestrel—Dyspnoea—Etoposide—testicular cancer	0.000516	0.0011	CcSEcCtD
Levonorgestrel—Somnolence—Etoposide—testicular cancer	0.000515	0.0011	CcSEcCtD
Levonorgestrel—Pneumonia—Epirubicin—testicular cancer	0.000512	0.00109	CcSEcCtD
Levonorgestrel—Nausea—Bleomycin—testicular cancer	0.00051	0.00109	CcSEcCtD
Levonorgestrel—Infestation—Epirubicin—testicular cancer	0.000509	0.00108	CcSEcCtD
Levonorgestrel—Infestation NOS—Epirubicin—testicular cancer	0.000509	0.00108	CcSEcCtD
Levonorgestrel—Vomiting—Dactinomycin—testicular cancer	0.000509	0.00108	CcSEcCtD
Levonorgestrel—Bronchitis—Doxorubicin—testicular cancer	0.000508	0.00108	CcSEcCtD
Levonorgestrel—Rash—Dactinomycin—testicular cancer	0.000505	0.00107	CcSEcCtD
Levonorgestrel—Decreased appetite—Etoposide—testicular cancer	0.000504	0.00107	CcSEcCtD
Levonorgestrel—Diarrhoea—Ifosfamide—testicular cancer	0.000502	0.00107	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Etoposide—testicular cancer	0.0005	0.00106	CcSEcCtD
Levonorgestrel—Body temperature increased—Cisplatin—testicular cancer	0.0005	0.00106	CcSEcCtD
Levonorgestrel—Fatigue—Etoposide—testicular cancer	0.000499	0.00106	CcSEcCtD
Levonorgestrel—Constipation—Etoposide—testicular cancer	0.000495	0.00105	CcSEcCtD
Levonorgestrel—Pain—Etoposide—testicular cancer	0.000495	0.00105	CcSEcCtD
Levonorgestrel—Urinary tract infection—Epirubicin—testicular cancer	0.000495	0.00105	CcSEcCtD
Levonorgestrel—Dysuria—Doxorubicin—testicular cancer	0.000494	0.00105	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000491	0.00105	CcSEcCtD
Levonorgestrel—Haemoglobin—Methotrexate—testicular cancer	0.000491	0.00104	CcSEcCtD
Levonorgestrel—Haemorrhage—Methotrexate—testicular cancer	0.000488	0.00104	CcSEcCtD
Levonorgestrel—Pollakiuria—Doxorubicin—testicular cancer	0.000488	0.00104	CcSEcCtD
Levonorgestrel—Dizziness—Ifosfamide—testicular cancer	0.000485	0.00103	CcSEcCtD
Levonorgestrel—Pharyngitis—Methotrexate—testicular cancer	0.000485	0.00103	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Methotrexate—testicular cancer	0.000482	0.00103	CcSEcCtD
Levonorgestrel—Weight increased—Doxorubicin—testicular cancer	0.000481	0.00102	CcSEcCtD
Levonorgestrel—Urethral disorder—Methotrexate—testicular cancer	0.000479	0.00102	CcSEcCtD
Levonorgestrel—Weight decreased—Doxorubicin—testicular cancer	0.000478	0.00102	CcSEcCtD
Levonorgestrel—Sinusitis—Epirubicin—testicular cancer	0.000478	0.00102	CcSEcCtD
Levonorgestrel—Nausea—Dactinomycin—testicular cancer	0.000475	0.00101	CcSEcCtD
Levonorgestrel—Pneumonia—Doxorubicin—testicular cancer	0.000474	0.00101	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Etoposide—testicular cancer	0.000474	0.00101	CcSEcCtD
Levonorgestrel—Infestation—Doxorubicin—testicular cancer	0.000471	0.001	CcSEcCtD
Levonorgestrel—Infestation NOS—Doxorubicin—testicular cancer	0.000471	0.001	CcSEcCtD
Levonorgestrel—Visual impairment—Methotrexate—testicular cancer	0.000471	0.001	CcSEcCtD
Levonorgestrel—Vomiting—Ifosfamide—testicular cancer	0.000466	0.000993	CcSEcCtD
Levonorgestrel—Hypersensitivity—Cisplatin—testicular cancer	0.000466	0.000992	CcSEcCtD
Levonorgestrel—Rash—Ifosfamide—testicular cancer	0.000462	0.000984	CcSEcCtD
Levonorgestrel—Dermatitis—Ifosfamide—testicular cancer	0.000462	0.000984	CcSEcCtD
Levonorgestrel—Erythema multiforme—Methotrexate—testicular cancer	0.000462	0.000983	CcSEcCtD
Levonorgestrel—Urticaria—Etoposide—testicular cancer	0.00046	0.00098	CcSEcCtD
Levonorgestrel—Haemoglobin—Epirubicin—testicular cancer	0.000459	0.000978	CcSEcCtD
Levonorgestrel—Rhinitis—Epirubicin—testicular cancer	0.000458	0.000975	CcSEcCtD
Levonorgestrel—Abdominal pain—Etoposide—testicular cancer	0.000458	0.000975	CcSEcCtD
Levonorgestrel—Body temperature increased—Etoposide—testicular cancer	0.000458	0.000975	CcSEcCtD
Levonorgestrel—Urinary tract infection—Doxorubicin—testicular cancer	0.000458	0.000975	CcSEcCtD
Levonorgestrel—Haemorrhage—Epirubicin—testicular cancer	0.000457	0.000973	CcSEcCtD
Levonorgestrel—Eye disorder—Methotrexate—testicular cancer	0.000456	0.000972	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Epirubicin—testicular cancer	0.000455	0.000968	CcSEcCtD
Levonorgestrel—Asthenia—Cisplatin—testicular cancer	0.000454	0.000966	CcSEcCtD
Levonorgestrel—Pharyngitis—Epirubicin—testicular cancer	0.000454	0.000966	CcSEcCtD
Levonorgestrel—Cardiac disorder—Methotrexate—testicular cancer	0.000453	0.000965	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Epirubicin—testicular cancer	0.000451	0.000961	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Epirubicin—testicular cancer	0.000449	0.000956	CcSEcCtD
Levonorgestrel—Urethral disorder—Epirubicin—testicular cancer	0.000448	0.000954	CcSEcCtD
Levonorgestrel—Sinusitis—Doxorubicin—testicular cancer	0.000442	0.000941	CcSEcCtD
Levonorgestrel—Immune system disorder—Methotrexate—testicular cancer	0.000441	0.000939	CcSEcCtD
Levonorgestrel—Visual impairment—Epirubicin—testicular cancer	0.00044	0.000938	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Methotrexate—testicular cancer	0.00044	0.000937	CcSEcCtD
Levonorgestrel—Nausea—Ifosfamide—testicular cancer	0.000436	0.000927	CcSEcCtD
Levonorgestrel—Diarrhoea—Cisplatin—testicular cancer	0.000433	0.000921	CcSEcCtD
Levonorgestrel—Erythema multiforme—Epirubicin—testicular cancer	0.000432	0.00092	CcSEcCtD
Levonorgestrel—Alopecia—Methotrexate—testicular cancer	0.000432	0.000919	CcSEcCtD
Levonorgestrel—Mental disorder—Methotrexate—testicular cancer	0.000428	0.000911	CcSEcCtD
Levonorgestrel—Eye disorder—Epirubicin—testicular cancer	0.000427	0.000909	CcSEcCtD
Levonorgestrel—Hypersensitivity—Etoposide—testicular cancer	0.000427	0.000909	CcSEcCtD
Levonorgestrel—Malnutrition—Methotrexate—testicular cancer	0.000425	0.000905	CcSEcCtD
Levonorgestrel—Erythema—Methotrexate—testicular cancer	0.000425	0.000905	CcSEcCtD
Levonorgestrel—Haemoglobin—Doxorubicin—testicular cancer	0.000425	0.000905	CcSEcCtD
Levonorgestrel—Cardiac disorder—Epirubicin—testicular cancer	0.000424	0.000903	CcSEcCtD
Levonorgestrel—Rhinitis—Doxorubicin—testicular cancer	0.000424	0.000903	CcSEcCtD
Levonorgestrel—Haemorrhage—Doxorubicin—testicular cancer	0.000423	0.0009	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Doxorubicin—testicular cancer	0.000421	0.000896	CcSEcCtD
Levonorgestrel—Pharyngitis—Doxorubicin—testicular cancer	0.00042	0.000894	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Doxorubicin—testicular cancer	0.000418	0.000889	CcSEcCtD
Levonorgestrel—Asthenia—Etoposide—testicular cancer	0.000416	0.000885	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Doxorubicin—testicular cancer	0.000416	0.000885	CcSEcCtD
Levonorgestrel—Urethral disorder—Doxorubicin—testicular cancer	0.000415	0.000883	CcSEcCtD
Levonorgestrel—Immune system disorder—Epirubicin—testicular cancer	0.000413	0.000879	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Epirubicin—testicular cancer	0.000412	0.000877	CcSEcCtD
Levonorgestrel—Back pain—Methotrexate—testicular cancer	0.000411	0.000875	CcSEcCtD
Levonorgestrel—Pruritus—Etoposide—testicular cancer	0.00041	0.000872	CcSEcCtD
Levonorgestrel—Arrhythmia—Epirubicin—testicular cancer	0.000408	0.000869	CcSEcCtD
Levonorgestrel—Visual impairment—Doxorubicin—testicular cancer	0.000408	0.000868	CcSEcCtD
Levonorgestrel—Alopecia—Epirubicin—testicular cancer	0.000404	0.00086	CcSEcCtD
Levonorgestrel—Vomiting—Cisplatin—testicular cancer	0.000402	0.000856	CcSEcCtD
Levonorgestrel—Mental disorder—Epirubicin—testicular cancer	0.0004	0.000852	CcSEcCtD
Levonorgestrel—Erythema multiforme—Doxorubicin—testicular cancer	0.0004	0.000851	CcSEcCtD
Levonorgestrel—Rash—Cisplatin—testicular cancer	0.000399	0.000849	CcSEcCtD
Levonorgestrel—Dermatitis—Cisplatin—testicular cancer	0.000398	0.000848	CcSEcCtD
Levonorgestrel—Malnutrition—Epirubicin—testicular cancer	0.000398	0.000847	CcSEcCtD
Levonorgestrel—Erythema—Epirubicin—testicular cancer	0.000398	0.000847	CcSEcCtD
Levonorgestrel—Diarrhoea—Etoposide—testicular cancer	0.000396	0.000844	CcSEcCtD
Levonorgestrel—Eye disorder—Doxorubicin—testicular cancer	0.000395	0.000841	CcSEcCtD
Levonorgestrel—Anaemia—Methotrexate—testicular cancer	0.000393	0.000837	CcSEcCtD
Levonorgestrel—Cardiac disorder—Doxorubicin—testicular cancer	0.000392	0.000836	CcSEcCtD
Levonorgestrel—Flatulence—Epirubicin—testicular cancer	0.000392	0.000835	CcSEcCtD
Levonorgestrel—Tension—Epirubicin—testicular cancer	0.00039	0.000831	CcSEcCtD
Levonorgestrel—Nervousness—Epirubicin—testicular cancer	0.000386	0.000823	CcSEcCtD
Levonorgestrel—Back pain—Epirubicin—testicular cancer	0.000385	0.000819	CcSEcCtD
Levonorgestrel—Dizziness—Etoposide—testicular cancer	0.000383	0.000815	CcSEcCtD
Levonorgestrel—Muscle spasms—Epirubicin—testicular cancer	0.000383	0.000814	CcSEcCtD
Levonorgestrel—Immune system disorder—Doxorubicin—testicular cancer	0.000382	0.000813	CcSEcCtD
Levonorgestrel—Vertigo—Methotrexate—testicular cancer	0.000382	0.000813	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Doxorubicin—testicular cancer	0.000381	0.000811	CcSEcCtD
Levonorgestrel—Arrhythmia—Doxorubicin—testicular cancer	0.000378	0.000804	CcSEcCtD
Levonorgestrel—Nausea—Cisplatin—testicular cancer	0.000376	0.0008	CcSEcCtD
Levonorgestrel—Alopecia—Doxorubicin—testicular cancer	0.000374	0.000796	CcSEcCtD
Levonorgestrel—Cough—Methotrexate—testicular cancer	0.000371	0.00079	CcSEcCtD
Levonorgestrel—Mental disorder—Doxorubicin—testicular cancer	0.000371	0.000789	CcSEcCtD
Levonorgestrel—Vomiting—Etoposide—testicular cancer	0.000368	0.000784	CcSEcCtD
Levonorgestrel—Erythema—Doxorubicin—testicular cancer	0.000368	0.000784	CcSEcCtD
Levonorgestrel—Malnutrition—Doxorubicin—testicular cancer	0.000368	0.000784	CcSEcCtD
Levonorgestrel—Anaemia—Epirubicin—testicular cancer	0.000368	0.000783	CcSEcCtD
Levonorgestrel—Rash—Etoposide—testicular cancer	0.000365	0.000778	CcSEcCtD
Levonorgestrel—Dermatitis—Etoposide—testicular cancer	0.000365	0.000777	CcSEcCtD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—MMP2—testicular cancer	0.000363	0.0146	CbGpPWpGaD
Levonorgestrel—Headache—Etoposide—testicular cancer	0.000363	0.000773	CcSEcCtD
Levonorgestrel—Flatulence—Doxorubicin—testicular cancer	0.000363	0.000772	CcSEcCtD
Levonorgestrel—Myalgia—Methotrexate—testicular cancer	0.000362	0.000771	CcSEcCtD
Levonorgestrel—Chest pain—Methotrexate—testicular cancer	0.000362	0.000771	CcSEcCtD
Levonorgestrel—Tension—Doxorubicin—testicular cancer	0.000361	0.000769	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000359	0.000765	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—KITLG—testicular cancer	0.000359	0.0144	CbGpPWpGaD
Levonorgestrel—Discomfort—Methotrexate—testicular cancer	0.000358	0.000761	CcSEcCtD
Levonorgestrel—Nervousness—Doxorubicin—testicular cancer	0.000358	0.000761	CcSEcCtD
Levonorgestrel—Vertigo—Epirubicin—testicular cancer	0.000357	0.000761	CcSEcCtD
Levonorgestrel—Syncope—Epirubicin—testicular cancer	0.000357	0.00076	CcSEcCtD
Levonorgestrel—ESR1—FOXM1 transcription factor network—MMP2—testicular cancer	0.000356	0.0143	CbGpPWpGaD
Levonorgestrel—Back pain—Doxorubicin—testicular cancer	0.000356	0.000758	CcSEcCtD
Levonorgestrel—Muscle spasms—Doxorubicin—testicular cancer	0.000354	0.000753	CcSEcCtD
Levonorgestrel—Palpitations—Epirubicin—testicular cancer	0.000352	0.000749	CcSEcCtD
Levonorgestrel—Loss of consciousness—Epirubicin—testicular cancer	0.00035	0.000744	CcSEcCtD
Levonorgestrel—Cough—Epirubicin—testicular cancer	0.000347	0.000739	CcSEcCtD
Levonorgestrel—Infection—Methotrexate—testicular cancer	0.000345	0.000734	CcSEcCtD
Levonorgestrel—Nausea—Etoposide—testicular cancer	0.000344	0.000733	CcSEcCtD
Levonorgestrel—Hypertension—Epirubicin—testicular cancer	0.000344	0.000731	CcSEcCtD
Levonorgestrel—Nervous system disorder—Methotrexate—testicular cancer	0.00034	0.000724	CcSEcCtD
Levonorgestrel—Anaemia—Doxorubicin—testicular cancer	0.00034	0.000724	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000339	0.0136	CbGpPWpGaD
Levonorgestrel—Chest pain—Epirubicin—testicular cancer	0.000339	0.000721	CcSEcCtD
Levonorgestrel—Myalgia—Epirubicin—testicular cancer	0.000339	0.000721	CcSEcCtD
Levonorgestrel—Anxiety—Epirubicin—testicular cancer	0.000338	0.000719	CcSEcCtD
Levonorgestrel—Skin disorder—Methotrexate—testicular cancer	0.000337	0.000717	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000336	0.000716	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Methotrexate—testicular cancer	0.000335	0.000714	CcSEcCtD
Levonorgestrel—Discomfort—Epirubicin—testicular cancer	0.000335	0.000712	CcSEcCtD
Levonorgestrel—Vertigo—Doxorubicin—testicular cancer	0.000331	0.000704	CcSEcCtD
Levonorgestrel—Anorexia—Methotrexate—testicular cancer	0.000331	0.000704	CcSEcCtD
Levonorgestrel—Syncope—Doxorubicin—testicular cancer	0.00033	0.000703	CcSEcCtD
Levonorgestrel—Palpitations—Doxorubicin—testicular cancer	0.000325	0.000693	CcSEcCtD
Levonorgestrel—Oedema—Epirubicin—testicular cancer	0.000325	0.000691	CcSEcCtD
Levonorgestrel—Loss of consciousness—Doxorubicin—testicular cancer	0.000324	0.000689	CcSEcCtD
Levonorgestrel—Infection—Epirubicin—testicular cancer	0.000323	0.000687	CcSEcCtD
Levonorgestrel—Cough—Doxorubicin—testicular cancer	0.000321	0.000684	CcSEcCtD
Levonorgestrel—Shock—Epirubicin—testicular cancer	0.000319	0.00068	CcSEcCtD
Levonorgestrel—Nervous system disorder—Epirubicin—testicular cancer	0.000318	0.000678	CcSEcCtD
Levonorgestrel—Hypertension—Doxorubicin—testicular cancer	0.000318	0.000677	CcSEcCtD
Levonorgestrel—CYP19A1—Biological oxidations—HPGDS—testicular cancer	0.000317	0.0127	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000316	0.000673	CcSEcCtD
Levonorgestrel—Skin disorder—Epirubicin—testicular cancer	0.000315	0.000671	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Epirubicin—testicular cancer	0.000314	0.000668	CcSEcCtD
Levonorgestrel—Insomnia—Methotrexate—testicular cancer	0.000314	0.000668	CcSEcCtD
Levonorgestrel—Myalgia—Doxorubicin—testicular cancer	0.000313	0.000667	CcSEcCtD
Levonorgestrel—Chest pain—Doxorubicin—testicular cancer	0.000313	0.000667	CcSEcCtD
Levonorgestrel—Anxiety—Doxorubicin—testicular cancer	0.000312	0.000665	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000311	0.000663	CcSEcCtD
Levonorgestrel—Discomfort—Doxorubicin—testicular cancer	0.00031	0.000659	CcSEcCtD
Levonorgestrel—Anorexia—Epirubicin—testicular cancer	0.00031	0.000659	CcSEcCtD
Levonorgestrel—Dyspnoea—Methotrexate—testicular cancer	0.000309	0.000659	CcSEcCtD
Levonorgestrel—Somnolence—Methotrexate—testicular cancer	0.000308	0.000657	CcSEcCtD
Levonorgestrel—Dyspepsia—Methotrexate—testicular cancer	0.000305	0.00065	CcSEcCtD
Levonorgestrel—Decreased appetite—Methotrexate—testicular cancer	0.000302	0.000642	CcSEcCtD
Levonorgestrel—Oedema—Doxorubicin—testicular cancer	0.0003	0.00064	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Methotrexate—testicular cancer	0.0003	0.000638	CcSEcCtD
Levonorgestrel—Fatigue—Methotrexate—testicular cancer	0.000299	0.000637	CcSEcCtD
Levonorgestrel—Infection—Doxorubicin—testicular cancer	0.000298	0.000635	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000297	0.0119	CbGpPWpGaD
Levonorgestrel—Pain—Methotrexate—testicular cancer	0.000297	0.000632	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000296	0.00063	CcSEcCtD
Levonorgestrel—Shock—Doxorubicin—testicular cancer	0.000296	0.000629	CcSEcCtD
Levonorgestrel—Nervous system disorder—Doxorubicin—testicular cancer	0.000295	0.000627	CcSEcCtD
Levonorgestrel—Insomnia—Epirubicin—testicular cancer	0.000294	0.000625	CcSEcCtD
Levonorgestrel—Skin disorder—Doxorubicin—testicular cancer	0.000292	0.000621	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Doxorubicin—testicular cancer	0.00029	0.000618	CcSEcCtD
Levonorgestrel—Dyspnoea—Epirubicin—testicular cancer	0.000289	0.000616	CcSEcCtD
Levonorgestrel—Somnolence—Epirubicin—testicular cancer	0.000289	0.000615	CcSEcCtD
Levonorgestrel—Anorexia—Doxorubicin—testicular cancer	0.000286	0.00061	CcSEcCtD
Levonorgestrel—Dyspepsia—Epirubicin—testicular cancer	0.000286	0.000608	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Methotrexate—testicular cancer	0.000284	0.000604	CcSEcCtD
Levonorgestrel—Decreased appetite—Epirubicin—testicular cancer	0.000282	0.000601	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00028	0.000597	CcSEcCtD
Levonorgestrel—Fatigue—Epirubicin—testicular cancer	0.00028	0.000596	CcSEcCtD
Levonorgestrel—Constipation—Epirubicin—testicular cancer	0.000278	0.000591	CcSEcCtD
Levonorgestrel—Pain—Epirubicin—testicular cancer	0.000278	0.000591	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—testicular cancer	0.000276	0.0111	CbGpPWpGaD
Levonorgestrel—Urticaria—Methotrexate—testicular cancer	0.000276	0.000587	CcSEcCtD
Levonorgestrel—Body temperature increased—Methotrexate—testicular cancer	0.000274	0.000584	CcSEcCtD
Levonorgestrel—Abdominal pain—Methotrexate—testicular cancer	0.000274	0.000584	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000274	0.000583	CcSEcCtD
Levonorgestrel—Insomnia—Doxorubicin—testicular cancer	0.000272	0.000579	CcSEcCtD
Levonorgestrel—ESR1—ATF-2 transcription factor network—MMP2—testicular cancer	0.000272	0.0109	CbGpPWpGaD
Levonorgestrel—Dyspnoea—Doxorubicin—testicular cancer	0.000268	0.00057	CcSEcCtD
Levonorgestrel—Somnolence—Doxorubicin—testicular cancer	0.000267	0.000569	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—FGFR3—testicular cancer	0.000267	0.0107	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Epirubicin—testicular cancer	0.000266	0.000565	CcSEcCtD
Levonorgestrel—Dyspepsia—Doxorubicin—testicular cancer	0.000264	0.000563	CcSEcCtD
Levonorgestrel—Decreased appetite—Doxorubicin—testicular cancer	0.000261	0.000556	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000261	0.0105	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000259	0.000552	CcSEcCtD
Levonorgestrel—Fatigue—Doxorubicin—testicular cancer	0.000259	0.000551	CcSEcCtD
Levonorgestrel—Urticaria—Epirubicin—testicular cancer	0.000258	0.000549	CcSEcCtD
Levonorgestrel—Pain—Doxorubicin—testicular cancer	0.000257	0.000547	CcSEcCtD
Levonorgestrel—Constipation—Doxorubicin—testicular cancer	0.000257	0.000547	CcSEcCtD
Levonorgestrel—Abdominal pain—Epirubicin—testicular cancer	0.000257	0.000546	CcSEcCtD
Levonorgestrel—Body temperature increased—Epirubicin—testicular cancer	0.000257	0.000546	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000256	0.0102	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Methotrexate—testicular cancer	0.000256	0.000544	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—HPGDS—testicular cancer	0.00025	0.01	CbGpPWpGaD
Levonorgestrel—Asthenia—Methotrexate—testicular cancer	0.000249	0.00053	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000246	0.00986	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000246	0.000523	CcSEcCtD
Levonorgestrel—Pruritus—Methotrexate—testicular cancer	0.000245	0.000523	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—KIT—testicular cancer	0.000245	0.00981	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Epirubicin—testicular cancer	0.000239	0.000509	CcSEcCtD
Levonorgestrel—Urticaria—Doxorubicin—testicular cancer	0.000239	0.000508	CcSEcCtD
Levonorgestrel—Body temperature increased—Doxorubicin—testicular cancer	0.000238	0.000506	CcSEcCtD
Levonorgestrel—Abdominal pain—Doxorubicin—testicular cancer	0.000238	0.000506	CcSEcCtD
Levonorgestrel—Diarrhoea—Methotrexate—testicular cancer	0.000237	0.000505	CcSEcCtD
Levonorgestrel—Asthenia—Epirubicin—testicular cancer	0.000233	0.000496	CcSEcCtD
Levonorgestrel—Pruritus—Epirubicin—testicular cancer	0.00023	0.000489	CcSEcCtD
Levonorgestrel—Dizziness—Methotrexate—testicular cancer	0.000229	0.000488	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000229	0.00917	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Epirubicin—testicular cancer	0.000222	0.000473	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—DNMT3L—testicular cancer	0.000222	0.0089	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Doxorubicin—testicular cancer	0.000221	0.000471	CcSEcCtD
Levonorgestrel—Vomiting—Methotrexate—testicular cancer	0.000221	0.00047	CcSEcCtD
Levonorgestrel—Rash—Methotrexate—testicular cancer	0.000219	0.000466	CcSEcCtD
Levonorgestrel—Dermatitis—Methotrexate—testicular cancer	0.000219	0.000465	CcSEcCtD
Levonorgestrel—Headache—Methotrexate—testicular cancer	0.000217	0.000463	CcSEcCtD
Levonorgestrel—Asthenia—Doxorubicin—testicular cancer	0.000216	0.000459	CcSEcCtD
Levonorgestrel—Dizziness—Epirubicin—testicular cancer	0.000215	0.000457	CcSEcCtD
Levonorgestrel—Pruritus—Doxorubicin—testicular cancer	0.000213	0.000453	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—KITLG—testicular cancer	0.000211	0.00844	CbGpPWpGaD
Levonorgestrel—Vomiting—Epirubicin—testicular cancer	0.000206	0.00044	CcSEcCtD
Levonorgestrel—Nausea—Methotrexate—testicular cancer	0.000206	0.000439	CcSEcCtD
Levonorgestrel—Diarrhoea—Doxorubicin—testicular cancer	0.000206	0.000438	CcSEcCtD
Levonorgestrel—Rash—Epirubicin—testicular cancer	0.000205	0.000436	CcSEcCtD
Levonorgestrel—Dermatitis—Epirubicin—testicular cancer	0.000205	0.000435	CcSEcCtD
Levonorgestrel—Headache—Epirubicin—testicular cancer	0.000203	0.000433	CcSEcCtD
Levonorgestrel—Dizziness—Doxorubicin—testicular cancer	0.000199	0.000423	CcSEcCtD
Levonorgestrel—Nausea—Epirubicin—testicular cancer	0.000193	0.000411	CcSEcCtD
Levonorgestrel—Vomiting—Doxorubicin—testicular cancer	0.000191	0.000407	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.00019	0.0076	CbGpPWpGaD
Levonorgestrel—Rash—Doxorubicin—testicular cancer	0.000189	0.000403	CcSEcCtD
Levonorgestrel—Dermatitis—Doxorubicin—testicular cancer	0.000189	0.000403	CcSEcCtD
Levonorgestrel—Headache—Doxorubicin—testicular cancer	0.000188	0.000401	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—STK11—testicular cancer	0.000181	0.00727	CbGpPWpGaD
Levonorgestrel—Nausea—Doxorubicin—testicular cancer	0.000178	0.00038	CcSEcCtD
Levonorgestrel—AR—Gene Expression—DNMT3L—testicular cancer	0.000169	0.00678	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—INSL3—testicular cancer	0.000158	0.00632	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—FGFR3—testicular cancer	0.000157	0.00627	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—KIT—testicular cancer	0.000144	0.00576	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—DNMT3L—testicular cancer	0.00013	0.00522	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000122	0.00488	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—INSL3—testicular cancer	9.27e-05	0.00371	CbGpPWpGaD
Levonorgestrel—CYP3A4—Biological oxidations—HPGDS—testicular cancer	9.25e-05	0.00371	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—H2AFZ—testicular cancer	7.77e-05	0.00311	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—H2AFZ—testicular cancer	5.92e-05	0.00237	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—HPGDS—testicular cancer	5.42e-05	0.00217	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—H2AFZ—testicular cancer	5.06e-05	0.00202	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—STK11—testicular cancer	5.03e-05	0.00201	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KITLG—testicular cancer	4.65e-05	0.00186	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—H2AFZ—testicular cancer	4.56e-05	0.00183	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—STK11—testicular cancer	3.94e-05	0.00158	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FGFR3—testicular cancer	3.46e-05	0.00138	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KIT—testicular cancer	3.17e-05	0.00127	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—H2AFZ—testicular cancer	2.97e-05	0.00119	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—STK11—testicular cancer	2.95e-05	0.00118	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KITLG—testicular cancer	2.73e-05	0.00109	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGFR3—testicular cancer	2.03e-05	0.000812	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KIT—testicular cancer	1.86e-05	0.000746	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HPGDS—testicular cancer	1.58e-05	0.000634	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—STK11—testicular cancer	1.15e-05	0.000461	CbGpPWpGaD
